Back-to-back Studies Validate geneType Breast Cancer Risk Test
MELBOURNE, Australia, March 13, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader...
Day: March 13, 2023
ORYZON Announces Clinical Candidate Nomination of ORY-4001 for the Treatment of CNS Disorders
A highly selective HDAC-6 inhibitorRescues motor-neuronal deficiencies in a Charcot-Marie-Tooth modelTo start IND enabling studiesMADRID, Spain and BOSTON, March 13,...
STRATA Skin Sciences Affirms No Exposure to Silicon Valley Bank
HORSHAM, Pa., March 13, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to...
PepGen Announces Upcoming Data Presentations at the 2023 Annual Muscle Dystrophy Association Clinical and Scientific Conference
BOSTON, March 13, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of...
BioVie Announces the Pausing of Patient Enrollment in Ascites Phase 2b Trial, Encouraging Efficacy Data is Announced, Initiating FDA Discussions to Conduct Pivotal Registrational Trial
Patients treated with BIV201 experienced reduced ascites fluid buildup (pCARSON CITY, Nev., March 13, 2023 (GLOBE NEWSWIRE) -- BioVie Inc.,...
electroCore Announces Poster to be Presented at the 2023 American Academy of Neurology Annual Scientific Meeting
Poster Highlights the Ability of Non-Invasive Vagus Nerve Stimulation (nVNS) to Accelerate Learning of a Second LanguageROCKAWAY, N.J., March 13,...
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results
OV329 Phase 1 trial is progressing on trackAn IV formulation candidate suitable for future clinical trials has been achieved for...
First Wave BioPharma Announces $4.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
BOCA RATON, Fla., March 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. ("First Wave BioPharma" or the “Company”) (NASDAQ:...
Israel’s Ministry of Labor Names Pluri as Winner of the 2022 Egalitarian Employment Award for its Commitment to Gender Diversity and Pay Equity
Chen Franco-Yehuda Chief Financial Officer Efrat Livne-Hadass Vice President of Human ResourcesHAIFA, Israel, March 13, 2023 (GLOBE NEWSWIRE) -- Pluri...
iCAD Announces Leadership Transition
Stacey Stevens Resigns as President and CEO and as a Member of the Board Dana Brown Named President and CEO,...
High Intra-Tumor TGF-β2 Predicts Poor Survival in Pediatric Cancer of the Brainstem
-The TGFβ1 and TGFβ3 isoforms are predictive --Validation of TGFβ2 as therapeutic target AGOURA HILLS, Calif., March 13, 2023 (GLOBE...
Aridis Meets Primary and Secondary Endpoints in Phase 2a Study of AR-501 in Cystic Fibrosis Patients
The study achieved high uptake of AR-501 in the respiratory tract at levels that were more than 50-fold higher than...
Mesa Laboratories, Inc. Reports Immaterial Financial Exposure to Silicon Valley Bank Closure
LAKEWOOD, Colo., March 13, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or the “Company”) is a global leader...
VectivBio and Asahi Kasei Pharma Announce the Start of a Phase 1 Study of Apraglutide in Japan
Single-dose study to assess pharmacokinetics, pharmacological activity, safety and tolerability in healthy Japanese men and womenBASEL, Switzerland, March 13, 2023...
BioNTech to Report Full Year and Fourth Quarter 2022 Financial Results and Operational Update on March 27, 2023
MAINZ, Germany, March 13, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial...
VitalHub Announces Licensing of SHREWD Solution in Canada, With The Winnipeg Regional Health Authority
TORONTO, March 13, 2023 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI) (OTCQX:VHIBF) is pleased to announce...
BioSig Confirms No Exposure to Silicon Valley Bank
Westport, CT, March 13, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital...
Mersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial
CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering...
Gracell Biotechnologies Reports Fourth Quarter and Full Year 2022 Unaudited Financial Results, and Provides Corporate Update
Plan to commence Phase 1b/2 clinical trial in US evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM)...